NEW YORK, NY – ( NewMediaWire ) – April 15, 2024 – Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Zoetis Inc. (“Zoetis” or the “Company”) (NYSE: ZTS). Click here to join the investigation.
If you invested in Zoetis and would like to discuss our investigation, please click here or contact us by emailing [email protected] or by calling (646) 315-9003.
On April 12, 2024, The Wall Street Journal published an article concerning Zoetis reporting that health regulators in the U.S. and Europe have received thousands of complaints about Zoetis’ arthritis drugs for pets – Librela for dogs and Solensia for cats – due to negative side effects. The article also reports that regulators in the U.S. and Europe are conducting reviews of the drugs.
Following this news, the price of Zoetis shares declined by $12.75 per share, or 7.84%, to close at $149.98 per share on April 12, 2024.
WHY CONTACT KAPLAN FOX – Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this investigation, please contact:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
E-mail: [email protected]
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707
E-mail: [email protected]
